Infinity Pharmaceuticals Inc. (INFI)

1.31
1.09 45.42
NASDAQ : Health Technology
Prev Close 2.40
Open 2.10
Day Low/High 1.26 / 2.10
52 Wk Low/High 1.65 / 2.92
Volume 4.58M
Avg Volume 405.60K
Exchange NASDAQ
Shares Outstanding 56.87M
Market Cap 137.05M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Bristol-Myers Squibb And Infinity Pharmaceuticals Announce A New Clinical Collaboration To Evaluate Opdivo (Nivolumab) In Combination With IPI-549 In Urothelial Cancer

Bristol-Myers Squibb And Infinity Pharmaceuticals Announce A New Clinical Collaboration To Evaluate Opdivo (Nivolumab) In Combination With IPI-549 In Urothelial Cancer

Bristol-Myers Squibb Company (NYSE: BMY) and Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb's Opdivo in combination with Infinity's IPI-549 in patients with advanced urothelial...

Infinity Announces IPI-549 Late-Breaking Presentation At SITC 33rd Annual Meeting

Infinity Announces IPI-549 Late-Breaking Presentation At SITC 33rd Annual Meeting

-- Combination Expansion Data from the IPI-549 MARIO-1 Phase 1b Study to be Presented --

Infinity To Present At BIO Investor Forum

Infinity To Present At BIO Investor Forum

CAMBRIDGE, Mass., Oct.

Infinity To Present At Cantor Fitzgerald Global Healthcare Conference

Infinity To Present At Cantor Fitzgerald Global Healthcare Conference

CAMBRIDGE, Mass., Sept.

Infinity To Present At Three Upcoming Investor Conferences In September

Infinity To Present At Three Upcoming Investor Conferences In September

CAMBRIDGE, Mass., Aug.

Infinity Pharmaceuticals Provides Company Update And Second Quarter 2018 Financial Results

Infinity Pharmaceuticals Provides Company Update And Second Quarter 2018 Financial Results

- Dr. Samuel Agresta Appointed as Chief Medical Officer -

Infinity Pharmaceuticals Appoints Samuel Agresta, M.D., M.P.H. As Chief Medical Officer

Infinity Pharmaceuticals Appoints Samuel Agresta, M.D., M.P.H. As Chief Medical Officer

- Key Addition to Infinity's Clinical Development Team Brings Recent Experience Leading First-in-Class, Targeted Oncology Programs Through FDA Approvals -

Infinity Announces The Date Of Its Second Quarter 2018 Financial Results Conference Call And Webcast

Infinity Announces The Date Of Its Second Quarter 2018 Financial Results Conference Call And Webcast

CAMBRIDGE, Mass., July 31, 2018 /PRNewswire/ -- Infinity Pharmaceuticals, Inc.

Arcus Biosciences And Infinity Pharmaceuticals Announce Clinical Collaboration To Evaluate Lead Programs In Triple-Combination Studies

Arcus Biosciences And Infinity Pharmaceuticals Announce Clinical Collaboration To Evaluate Lead Programs In Triple-Combination Studies

- IPI-549 with AB928 and AB122 in Triple Negative Breast Cancer and Ovarian Cancer -

Arcus Biosciences And Infinity Pharmaceuticals Announce Clinical Collaboration To Evaluate Lead Programs In Triple-Combination Studies

Arcus Biosciences And Infinity Pharmaceuticals Announce Clinical Collaboration To Evaluate Lead Programs In Triple-Combination Studies

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, and Infinity Pharmaceuticals, Inc.

Infinity Reports IPI-549 Clinical And Translational Data From Ongoing Phase 1/1b Study At American Society Of Clinical Oncology Annual Meeting

Infinity Reports IPI-549 Clinical And Translational Data From Ongoing Phase 1/1b Study At American Society Of Clinical Oncology Annual Meeting

- IPI-549 Well Tolerated in Combination Dose Escalation with Nivolumab -

Serametrix MDSC Assay Being Utilized By Infinity Pharmaceuticals In The First Clinical Study To Prospectively Identify Patients With High Blood Levels Of MDSCs

Serametrix MDSC Assay Being Utilized By Infinity Pharmaceuticals In The First Clinical Study To Prospectively Identify Patients With High Blood Levels Of MDSCs

Today Serametrix Corporation announced that Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) has enrolled the first patient in a clinical trial in which the Serametrix MDSC Assay is being used to pre-select patients having high baseline blood levels of...

First Week of INFI July 2018 Options Trading

First Week of INFI July 2018 Options Trading

Investors in Infinity Pharmaceuticals Inc saw new options begin trading this week, for the July 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 211 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

First Week Of December 15th Options Trading For Infinity Pharmaceuticals (INFI)

First Week Of December 15th Options Trading For Infinity Pharmaceuticals (INFI)

Investors in Infinity Pharmaceuticals Inc saw new options become available this week, for the December 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INFI options chain for the new December 15th contracts and identified one put and one call contract of particular interest.

This Market Action Is Not Creating Many Setups

This Market Action Is Not Creating Many Setups

Until market conditions shift, I won't be making any sizable buys.

Short Interest In Infinity Pharmaceuticals Declines 17.6%

The most recent short interest data has been released for the 04/13/2017 settlement date, which shows a 591,228 share decrease in total short interest for Infinity Pharmaceuticals Inc , to 2,765,545, a decrease of 17.61% since 03/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Dow Needs to Hit 20K to Shake Things Up

Market has fallen into a dull pattern.

Don't Tell Anyone: Insiders Are Buying These Stocks Like Crazy

Don't Tell Anyone: Insiders Are Buying These Stocks Like Crazy

Insiders at Infinity Pharmaceuticals and Och-Ziff Capital Management Group -- among other companies -- have been scooping up shares of their own stock lately.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies -- including Wynn Resorts and Virtu Financial -- have been scooping up shares of their own stock lately.

Notable Friday Option Activity: INFI, RSO, P

Notable Friday Option Activity: INFI, RSO, P

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Infinity Pharmaceuticals Inc , where a total volume of 7,196 contracts has been traded thus far today, a contract volume which is representative of approximately 719,600 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 130.3% of INFI's average daily trading volume over the past month, of 552,295 shares.

Verastem Licenses Duvelisib From Infinity Pharmaceuticals

Verastem Licenses Duvelisib From Infinity Pharmaceuticals

Verastem, Inc. (NASDAQ:VSTM) and Infinity Pharmaceuticals, Inc.

Short Interest Jumps 24.6% For INFI

Short Interest Jumps 24.6% For INFI

The most recent short interest data has been released for the 10/14/2016 settlement date, which shows a 408,920 share increase in total short interest for Infinity Pharmaceuticals Inc , to 2,067,803, an increase of 24.65% since 09/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Infinity Pharmaceuticals (INFI) Stock Rises on 'Favorable' Cancer Drug Trial Results

Infinity Pharmaceuticals (INFI) Stock Rises on 'Favorable' Cancer Drug Trial Results

Infinity Pharmaceuticals (INFI) said preliminary results from its IPI-549 drug trial showed that the cancer treatment can reverse tumor resistance to checkpoint inhibitors.

7 Stocks Under $10 to Trade for Big Post-Brexit Gains

7 Stocks Under $10 to Trade for Big Post-Brexit Gains

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

TheStreet Quant Rating: D (Sell)